Beh?et’s disease ocular attack score 24: evaluation of ocular disease activity before and after initiation of infliximab
详细信息 查看全文
- 作者：Toshikatsu Kaburaki (1)
Kenichi Namba (2)
Koh-hei Sonoda (3)
Takeshi Kezuka (4)
Hiroshi Keino (5)
Takako Fukuhara (2) (6)
Koju Kamoi (7)
Kei Nakai (8)
Nobuhisa Mizuki (9)
Nobuyuki Ohguro (10) - 关键词：Beh?et’s disease ; Ocular attack ; Score ; Disease activity ; Infliximab
- 刊名：Japanese Journal of Ophthalmology
- 出版年：2014
- 出版时间：March 2014
- 年：2014
- 卷：58
- 期：2
- 页码：120-130
- 全文大小：548 KB
- 参考文献：1. Ohguro N, Sonoda KH, Takeuchi M, Matsumura M, Mochizuki M. The 2009 prospective multi-center epidemiologic survey of uveitis in Japan. Jpn J Ophthalmol. 2012;56:432-. CrossRef
2. Nakae K, Masaki F, Hashimoto F, Inaba G, Mochizuki M, Sakane T. Recent epidemiological features of Beh?et’s disease in Japan. In: Godeau P, Wechsler B, editors. Beh?et’s disease. Amsterdam: Excerpta Medica; 1993. p. 145-1.
3. Mochizuki M, Akduman L, Nussenblatt RB. Beh?et disease. In: Pepose JS, Holland GN, Wilhelmus KR, editors. Ocular infection and immunity. St. Louis: Mosby; 1996. p. 663-5.
4. Evereklioglu C. Current concepts in the etiology and treatment of Beh?et disease. Surv Ophthalmol. 2005;50:297-50. CrossRef
5. Ohno S, Nakamura S, Hori S, Shimakawa M, Kawashima H, Mochizuki M, et al. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Beh?et’s disease with refractory uveoretinitis. J Rheumatol. 2004;31:1362-.
6. Sfikakis PP, Theodossiadis PG, Katsiari CG, Kaklamanis P, Markomichelakis NN. Effect of infliximab on sight-threatening panuveitis in Beh?et’s disease. Lancet. 2001;358:295-. CrossRef
7. Niccoli L, Nannini C, Benucci M, Chindamo D, Cassarà E, Salvarani C, et al. Long-term efficacy of infliximab in refractory posterior uveitis of Beh?et’s disease: a 24-month follow-up study. Rheumatology. 2007;46:1161-. CrossRef
8. Sfikakis PP, Iliopoulos A, Elezoglou A, Kittas C, Stratigos A. Psoriasis induced by anti-tumor necrosis factor therapy. Arthritis Rheum. 2005;52:2513-. CrossRef
9. Kawazoe Y, Sugita S, Yamada Y, Akino A, Miura K, Mochizuki M. Psoriasis triggered by infliximab in a patient with Beh?et’s disease. Jpn J Ophthalmol. 2013;57:95-. CrossRef
10. Yoshida A, Kawashima H, Motoyama Y, Shibui H, Kaburaki T, Shimizu K, et al. Comparison of patients with Behcet’s disease in the 1980s and 1990s. Ophthalmology. 2004;111:810-. CrossRef
11. Okada AA, Goto H, Ohno S, Mochizuki M, Ocular Beh?et’s Disease Research Group of Japan. Multicenter study of infliximab for refractory uveoretinitis in Beh?et disease. Arch Ophthalmol. 2012;130:592-. CrossRef
12. Kaburaki T, Araki F, Takamoto M, Okinaga K, Yoshida A, Numaga J, et al. Best-corrected visual acuity and frequency of ocular attacks during the initial 10?years in patients with Beh?et’s disease. Graefes Arch Clin Exp Ophthalmol. 2010;248:709-4. CrossRef
13. Bhakta BB, Brennan P, James TE, Chamberlain MA, Noble BA, Silman AJ. Beh?et’s disease: evaluation of a new instrument to measure clinical activity. Rheumatology (Oxford). 1999;38:728-3. CrossRef
14. Lawton G, Bhakta BB, Chamberlain MA, Tennant A. The Behcet’s disease activity index. Rheumatology (Oxford). 2004;43:73-. CrossRef
15. Gaujoux-Viala C, Mouterde G, Baillet A, Claudepierre P, Fautrel B, Le Lo?t X, et al. Evaluating disease activity in rheumatoid arthritis: which composite index is best? A systematic literature analysis of studies comparing the psychometric properties of the DAS, DAS28, SDAI and CDAI. Joint Bone Spine. 2012;79:149-5. CrossRef
16. Prevoo ML, van ‘t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38:44-. CrossRef
17. Smolen JS, Breedveld FC, Schiff MH, Kalden JR, Emery P, Eberl G, et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology. 2003;42:244-7. CrossRef
18. Aletaha D, Nell VP, Stamm T, Uffmann M, Pflugbeil S, Machold K, et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther. 2005;7:R796-06. CrossRef
19. Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol. 2005;140:509-6. CrossRef
20. Nussenblatt RB, Palestine AG, Chan CC, Roberge F. Standardization of vitreal inflammatory activity in intermediate and posterior uveitis. Ophthalmology. 1985;92:467-1. CrossRef - 作者单位：Toshikatsu Kaburaki (1)
Kenichi Namba (2)
Koh-hei Sonoda (3)
Takeshi Kezuka (4)
Hiroshi Keino (5)
Takako Fukuhara (2) (6)
Koju Kamoi (7)
Kei Nakai (8)
Nobuhisa Mizuki (9)
Nobuyuki Ohguro (10)
1. Department of Ophthalmology, University of Tokyo Graduate School of Medicine, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan
2. Department of Ophthalmology, Hokkaido University Graduate School of Medicine, Kita 15, Nishi 7, Kita-ku, Sapporo, Hokkaido, 060-8638, Japan
3. Department of Ophthalmology, Yamaguchi University Graduate School of Medicine, 1-1-1 Minami-Kogushi, Ube, Yamaguchi, 755-8505, Japan
4. Department of Ophthalmology, Tokyo Medical University School of Medicine, 6-1-1 Shinjuku, Shinjuku-ku, Tokyo, 160-8402, Japan
5. Department of Ophthalmology, Kyorin University School of Medicine, 6-20-2 Shinkawa, Mitaka, Tokyo, 181-8611, Japan
6. Department of Ophthalmology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan
7. Department of Ophthalmology, Tokyo Medical and Dental University School of Medicine, Yushima 1-5-45, Nishi 7, Bunkyo-ku, Tokyo, 113-8510, Japan
8. Department of Ophthalmology, Osaka University Graduate School of Medicine, Yamadaoka 2-2, Suita, Osaka, 565-0871, Japan
9. Department of Ophthalmology, Yokohama City University School of Medicine, Fukuura 3-9, Kanazawa-ku, Yokohama, Kanagawa, 236-0004, Japan
10. Department of Ophthalmology, Osaka Koseinenkin Hospital, 4-2-78 Fukushima, Fukushima-ku, Osaka, 553-0003, Japan - ISSN：1613-2246
文摘
Purpose We developed a novel scoring system for uveitis due to Beh?et’s disease (BD), termed Beh?et’s disease ocular attack score 24 (BOS24), and examined its validity and usefulness by estimating changes in ocular disease activities both before and after initiation of infliximab therapy. Methods BOS24 consists of a total 24 points divided into 6 parameters of ocular inflammatory symptoms. To examine the validity of our scoring system, 5 uveitis specialists examined the severity of 50 ocular attacks in clinical charts using both our system and a physician’s impression score (grade 1-0). In addition, ocular disease activities both before and after initiation of infliximab were retrospectively examined in 150 cases of ocular BD using BOS24. Results The average BOS24 for the 5 doctors was highly correlated with the average physician’s impression score (p?<?0.0001), whereas the coefficient of variance for BOS24 among doctors was much lower than that for the physician’s impression score (p?<?0.0001). Summation of BOS24 over a 6-month period (BOS24-6M) was significantly reduced after starting infliximab therapy (p?<?0.0001). The average BOS24 for individual ocular attacks was also significantly decreased after starting infliximab, with scores for the posterior pole and fovea notably improved. Conclusions BOS24 was highly related to severity noted by the physician’s impression and had a low level of variability among the examined doctors. Using our novel scoring system, infliximab therapy was shown to reduce not only the frequency of ocular attacks, but also the severity of each attack. BOS24 is a promising tool for evaluating ocular BD activities.